Enanta Pharmaceuticals logo
ENTAEnanta Pharmaceuticals
Trade ENTA now
Enanta Pharmaceuticals primary media

About Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA) focuses on discovering, developing, and commercializing small molecule drugs for the treatment of viral infections and liver diseases. Specializing in creating treatments for respiratory syncytial virus, hepatitis B virus, and human metapneumovirus, Enanta is committed to addressing unmet medical needs. Their projects range from preclinical to phase 2 development, showcasing their comprehensive approach to tackling complex diseases. With objectives centered around innovation, patient health, and expanding their pipeline of therapeutic candidates, Enanta aims to be at the forefront of transformative treatment solutions.

What is ENTA known for?

Snapshot

Public US
Ownership
1995
Year founded
145
Employees
Watertown, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Enanta Pharmaceuticals

  • Hepatitis C virus (HCV) regimens, offering a combination of direct-acting antivirals leading to high cure rates for infected patients.
  • Respiratory syncytial virus (RSV) programs, focusing on developing treatments for severe RSV infections in pediatric and adult populations.
  • Human Metapneumovirus and Parainfluenza Virus (hMPV/PIV) treatments, working on antiviral therapies for these lesser-known but impactful respiratory viruses.
  • Hepatitis B virus (HBV) therapeutic solutions, developing treatments to manage and potentially cure chronic HBV infections.
  • Coronavirus (COVID-19) research, exploring antiviral compounds to combat the SARS-CoV-2 virus and address the global pandemic.

Enanta Pharmaceuticals executive team

  • Dr. Jay R. Luly Ph.D.President, CEO & Director
  • Dr. Yat Sun Or Ph.D.Chief Scientific Officer
  • Dr. Scott T. Rottinghaus M.D.Chief Medical Officer
  • Mr. Harry R. Trout IIIInterim Principal Financial Officer
  • Ms. Kathleen S. Capps C.P.A.Interim Principal Accounting Officer
  • Ms. Jennifer VieraExecutive Director of Investor Relations & Corporate Communications
  • Mr. Matthew P. Kowalsky J.D.Chief Legal Officer & Corporate Secretary
  • Mr. Nathaniel S. Gardiner J.D.Consultant
  • Ms. Tara Lynn Kieffer Ph.D.Chief Product Strategy Officer
  • Mr. Brendan LuuChief Business Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.